R arthritis (RA) is a painful and disabling condition that is increasingly widely recognized as being associated with early mortality. Since the late 1970s, clinical trials have been conducted in both Europe and North America to determine whether oral cyclosporin A (CyA) has a role in the management of RA, and, if so, how it might best be used.
That experience, plus advances in our understanding of the mechanisms of action of CyA and the pathology of RA, provided the foundation for the recommendations of the 1992 International Consensus Report on the use of CyA in RA [1] . These recommendations were updated at a subsequent International Review in 1994 [2] . The advice presented below is derived from a further review of the recommendations, in which a trend towards early implementation of therapy, increased clinical experience with CyA, and the development of the new microemulsion formulation of CyA (Sandimmun Neoral 8 ) were taken into consideration. A secondary goal of the review was to provide clear and accessible guidance to physicians wishing to prescribe the CyA microemulsion to their patients with RA, within the context of specific national prescribing information. The assumption is made that CyA will be administered outside experimental research protocols by physicians experienced in the management of RA.
WHOM DO WE TREAT AND WHEN?
Clinical trials show CyA to be effective in patients with active RA. CyA may be considered for the treatment of patients who are candidates for secondline therapy, and should be selected on the same basis as other second-line agents. Furthermore, CyA may be used in patients with early persistent RA, and advanced RA, for whom CyA is considered to be the most appropriate available option in the view of both physician and patient. These recommendations are supported by the following considerations:
(i) the prognosis of RA remains poor, despite the earlier use of traditional disease-modifying antirheumatic drugs for most patients; (ii) clinical and radiographic evidence of disease progression can be used to identify more readily some patients who are likely to become severely affected by RA at an early stage of their disease; (iii) risk factors for CyA toxicity are now established and patients can be monitored appropriately.
WHOM SHOULD WE NOT TREAT? The following recommendations include contraindications for the use of CyA and situations in which caution is advised. However, it may on rare occasions be desirable to administer CyA, or indeed any medication, in the presence of a contraindication. A physician contemplating such a measure is advised to seek advice from colleagues and relevant specialists to make a fully informed risk/benefit assessment. 
Contraindications

Caution in use
The following factors increase the risk of adverse effects from CyA. If one of these factors is present, the potential risks of therapy should be weighed carefully against the benefits. Table I 
Continuing treatment
The overall aim of treatment with CyA is to titrate the dose according to efficacy and tolerability to achieve the optimum balance between benefit and risk.
If there is a clinical response after 4-8 weeks, and optimal efficacy is considered to have been achieved, continue at the same CyA dose.
If there is no clinical response or only a partial clinical response after 4-8 weeks, the CyA dose should be titrated upwards. Incremental increases of 0.5 to maximally 1.0 mg/kg are recommended at 1-to 2-month intervals, to a maximum dose of 5 mg/kg per day. Particular caution should be exercised with doses of q4.0 mg/kg per day.
If an effective maximum tolerable dose of CyA is being administered, and no further improvement is expected, and the patient has been stable for at least 3 months, the dose should be decreased monthly or every 2 months in increments of 0.5 mg/kg to the lowest effective dose. An effective dose is one agreed to be so by a consensus of the patient and physician.
If CyA is only partially effective after 3 months at the maximum tolerable dose, another medication should be considered to be used concomitantly or to replace CyA.
If there is essentially no clinical response by 6 months, and the maximum tolerable dose has been administered for at least 3 months, CyA should be discontinued.
The recommended dosing guidelines for the CyA microemulsion are summarized in the algorithm in Fig. 1 .
RECOMMENDED MONITORING GUIDELINES
TO OPTIMIZE TREATMENT These monitoring guidelines were originally developed at an earlier consensus conference on CyA for psoriasis [3] and were agreed at the previous International RA Consensus Meetings to be appropriate for patients with RA during the first 3 yr of therapy 
RECOMMENDED DOSING GUIDELINES TO OPTIMIZE TREATMENT
Initial treatment
The starting dose of the CyA microemulsion should be 2.5-3.0 mg/kg per day. The drug is recommended to be administered in a twice-daily oral regimen, although a single daily dose may be acceptable. good absorbers of CyA from the original formulation, the absorption of CyA is unlikely to change post-conversion. However, in patients who were poor absorbers of CyA from the original formulation, the absorption of CyA appears to increase post-conversion. As a result, it may be necessary to make subsequent dose reductions in these patients, to ensure that they are receiving the lowest effective dose. All dose adjustments post-conversion should be conducted according to the recommended dosing guidelines for safety and efficacy, and doses should not exceed 5 mg/kg body weight per day, with caution exercised with doses q4 mg/kg per day.
Careful safety monitoring is mandatory postconversion.
Blood pressure and serum creatinine should be measured prior to conversion and 2, 4 and 8 weeks thereafter.
If the patient exhibits abnormal blood pressure or serum creatinine values prior to conversion, caution should be exercised.
If the post-conversion blood pressure markedly exceeds the pre-conversion value, a reduction in CyA dose should be considered.
If the post-conversion serum creatinine rises to q30% above the patient's pre-treatment baseline value, the algorithm in Fig. 2 should be followed.
COMBINATION THERAPY
Evidence from at least two controlled, randomized clinical trials indicates that CyA in combination with other second-line agents produces clinically important benefit in the treatment of RA [4, 5] . On this basis, CyA could reasonably be considered for use in combination with second-line agents in patients who have exhibited suboptimal response to CyA alone.
This Consensus Conference took place in Rome, Italy, on 19 June 1996, under the sponsorship of [1, 2] . Data regarding the safety of CyA beyond that period continue to be accumulated.
The use of the CyA microemulsion must be carefully monitored and controlled, in the same way as the original formulation.
Regular clinical and laboratory examinations are essential.
Renal function (i.e. serum creatinine) and blood pressure should be monitored every 2 weeks for the first 3 months and then monthly if stable. More frequent monitoring is necessary if the CyA dose is increased or if there is a rise in serum creatinine or blood pressure.
If the serum creatinine is persistently raised by q30% of pre-treatment values, the algorithm shown in Fig. 2 should be followed to avoid renal damage.
Hypertension (diastolic blood pressure sustained at q95 mmHg) in a patient receiving CyA should be treated; however, antihypertensive agents that interfere with CyA metabolism should be avoided (see Table I ). The physician is also advised to add non-pharmacological approaches to the treatment of hypertension, for consistent control. In addition, the role of concomitant medication (especially NSAIDs) should be considered.
Routine measurement of CyA blood levels is not necessary, but may be of use under special circumstances, e.g. if there is concern over drug interactions, non-compliance or unusual drug bioavailability. In these cases, blood samples should be drawn 12 h after the last dose of CyA, which will usually be administered in two divided doses at 12 h intervals.
Other adverse events should be recorded, and the CyA dose should either be reduced in increments of 0.5-1.0 mg/kg or discontinued, depending on severity.
CONVERSION FROM THE ORIGINAL CYCLOSPORIN A FORMULATION TO THE
MICROEMULSION FORMULATION When converting patients from the original CyA formulation to the microemulsion formulation, a 1:1 dose-conversion strategy is recommended. The rationale for such an approach is that, in patients who are
